Bank of New York Mellon
IMVT icon

Bank of New York Mellon’s Immunovant IMVT Stock Holding History

Bank of New York Mellon’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.4M Buy
295,791
+79,566
+37% +$2.42M ﹤0.01% 1962
2026
Q1 		$5.37M Buy
216,225
+16,861
+8% +$437K ﹤0.01% 2268
2025
Q4 		$5.07M Sell
199,364
-2,591
-1% -$57.8K ﹤0.01% 2321
2025
Q3 		$3.26M Buy
201,955
+12,292
+6% +$199K ﹤0.01% 2559
2025
Q2 		$3.03M Sell
189,663
-12,248
-6% -$185K ﹤0.01% 2541
2025
Q1 		$3.45M Sell
201,911
-1,150
-0.6% -$24.1K ﹤0.01% 2417
2024
Q4 		$5.03M Buy
203,061
+62
+0% +$1.76K ﹤0.01% 2294
2024
Q3 		$5.79M Sell
202,999
-47,340
-19% -$1.4M ﹤0.01% 2222
2024
Q2 		$6.61M Buy
250,339
+27,960
+13% +$795K ﹤0.01% 2185
2024
Q1 		$7.19M Sell
222,379
-22,451
-9% -$819K ﹤0.01% 2145
2023
Q4 		$10.3M Buy
244,830
+52,616
+27% +$1.94M ﹤0.01% 1975
2023
Q3 		$7.38M Buy
192,214
+9,648
+5% +$218K ﹤0.01% 2122
2023
Q2 		$3.46M Buy
182,566
+13,492
+8% +$252K ﹤0.01% 2527
2023
Q1 		$2.62M Buy
169,074
+1,564
+0.9% +$27.1K ﹤0.01% 2642
2022
Q4 		$2.97M Buy
167,510
+17,836
+12% +$225K ﹤0.01% 2629
2022
Q3 		$835K Buy
149,674
+8,241
+6% +$40.3K ﹤0.01% 3295
2022
Q2 		$552K Sell
141,433
-5,366
-4% -$23.2K ﹤0.01% 3529
2022
Q1 		$809K Buy
146,799
+933
+0.6% +$5.81K ﹤0.01% 3440
2021
Q4 		$1.24M Buy
145,866
+5,393
+4% +$44.5K ﹤0.01% 3261
2021
Q3 		$1.22M Buy
140,473
+17,605
+14% +$159K ﹤0.01% 3288
2021
Q2 		$1.3M Sell
122,868
-26,082
-18% -$364K ﹤0.01% 3256
2021
Q1 		$2.39M Sell
148,950
-18,161
-11% -$479K ﹤0.01% 2829
2020
Q4 		$7.72M Buy
167,111
+12,665
+8% +$586K ﹤0.01% 2140
2020
Q3 		$5.43M Buy
154,446
+79,342
+106% +$2.39M ﹤0.01% 2169
2020
Q2 		$1.83M Buy
+75,104
New +$1.61M ﹤0.01% 2738

Other funds holding IMVT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Bank of New York Mellon's IMVT Position: Q2 2026 in Review

Bank of New York Mellon increased its Immunovant (IMVT) stake by 37% in Q2 2026, buying an estimated $2.42M and bringing the position to 295,791 shares worth $11.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1962.

Bank of New York Mellon first reported a position in IMVT in Q2 2020 and has held it in 25 quarters since. 73 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Bank of New York Mellon held 295,791 shares of Immunovant worth $11.4M as of Q2 2026.
  • Bank of New York Mellon bought 79,566 Immunovant shares in Q2 2026, an estimated $2.42M.
  • Immunovant made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1962 holding.
  • Bank of New York Mellon first reported a position in Immunovant in Q2 2020 and has held it in 25 quarters since.
  • 73 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.